Healthcare providers' use of a concise summary to prescribe for lactating patients
Teresa Koenig,Cynthia Robins,Paula Darby Lipman,Miriam Dinatale,Tamara Johnson,Leyla Sahin,Catherine Roca,Jeannie Limpert,Kristie Baisden,Yeruk Mulugeta,Lynne Yao,Kerri-Ann Jennings,Meghna Alimchandani,Darcie Everett,Audrey Gassman,Christina Chang,Christopher Ellis,Elimika Pfuma Fletcher,Sherbet Samuels
DOI: https://doi.org/10.1016/j.sapharm.2024.02.004
IF: 3.348
2024-02-20
Research in Social and Administrative Pharmacy
Abstract:Background Most breastfeeding individuals take at least one prescription drug, yet limited data from lactation studies are available to inform the safety of these drugs during breastfeeding. As a result, healthcare providers (HCPs) rely on available information about safety of drugs used during pregnancy or on personal experiences to inform prescribing/counseling decisions for breastfeeding individuals. To improve risk communication regarding drugs used during lactation, the U.S. Food and Drug Administration published the Pregnancy and Lactation Labeling Rule in 2015, which added a narrative summary of available risk information to the lactation section of Prescribing Information (PI). Prior studies on labeling in PLLR format revealed that although HCPs found these details valuable, they regarded the narrative as too long to support decision-making during patient encounters. Objective This qualitative study's objective was to assess the utility of adding a concise summary to the Lactation subsection of PI to complement the narrative and succinctly communicate to busy HCPs a drug's risks when used during lactation. The concise summary consisted of a bolded headline, bulleted descriptions of available study findings and potential adverse reactions, and recommendations for risk mitigation. Methods Twenty-five online focus groups were conducted with five segments of HCPs to obtain their feedback on the concise summary and discuss their prescribing/counseling decisions for four fictitious prescription drugs including one vaccine. Results HCPs utilized the concise summary to make initial prescribing/counseling decisions. Many also used the labeling narrative for a comprehensive benefit-risk assessment. Conclusion The findings indicate a need to continue to improve communication about safety of drugs used during lactation, and that the concise summary may help facilitate this communication. The study also highlights the need to educate HCPs about PI limitations when clinical data are lacking and the need to encourage clinical studies to be conducted to support actionable recommendations about use of prescription drugs during lactation.
public, environmental & occupational health